The future of warfarin pharmacogenetics in under-represented minority groups

Future Cardiology

Volumn 8, Issue 4, 2012, Pages 563-576

  Cavallari, Larisa H ^a   Perera, Minoli A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

African American; CYP2C9; Hispanic; polymorphism; VKORC1; warfarin

Indexed keywords

CALCIUM BINDING PROTEIN; CALUMENIN; CARBOXYLASE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; GAMMA GLUTAMYL CARBOXYLASE; LOSARTAN; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

AFRICAN AMERICAN; ASIAN; CAUCASIAN; DRUG METABOLISM; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; MINORITY GROUP; PHARMACOGENETICS; POPULATION GENETIC STRUCTURE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS;

AFRICAN AMERICANS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CALCIUM-BINDING PROTEINS; CARBON-CARBON LIGASES; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HISPANIC AMERICANS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MINORITY GROUPS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; STROKE; WARFARIN;

EID: 84864848323     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.31     Document Type: Review

References (83)

1. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with a trial fibrillation. Circulation 115(21), 2689-2696 (2007).
2. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349(11), 1019-1026 (2003).
3. Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009).
4. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365(21), 2002-2012 (2011).
5. Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: AMERICAN College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(Suppl. 6), S160-S198 (2008).
6. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 107(12), 1692-1711 (2003).
7. Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
8. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann. Pharmacother. 36(10), 1512-1517 (2002).
9. Limdi NA, Limdi MA, Cavallari L et al. Warfarin dosing in patients with impaired kidney function. Am. J. Kidney Dis. 56(5), 823-831 (2010).
10. Huang SW, Chen HS, Wang XQ et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: A prospective study in Chinese patients. Pharmacogenet. Genomics 19(3), 226-234 (2009).
11. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
12. Anderson JL, Horne BD, Stevens SM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22), 2563-2570 (2007).
13. Burmester JK, Berg RL, Yale SH et al. A randomized controlled trial of genotype-based coumadin initiation. Genet. Med. 13(6), 509-518 (2011).
14. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005).
15. Cooper GM, Johnson JA, Langaee TY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4), 1022-1027 (2008).
16. Cha PC, Mushiroda T, Takahashi A et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19(23), 4735-4744 (2011).
17. Takeuchi F, McGinnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), E1000433 (2009).
18. Limdi NA, Arnett DK, Goldstein JA et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9(5), 511-526 (2008).
19. Scordo MG, Pengo V, Spina E et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72(6), 702-710 (2002).
20. Takahashi H, Kashima T, Nomizo Y et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin. Pharmacol. Ther. 63(5), 519-528 (1998).
21. Cavallari LH, Langaee TY, Momary KM et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87(4), 459-464 (2010).
22. Limdi NA, McGwin G, Goldstein JA et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83(2), 312-321 (2007).
23. Rost S, Fregin A, Ivaskevicius V et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974), 537-541 (2004).
24. D'Andrea G, D'Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2), 645-649 (2005).
25. Wang D, Chen H, Momary KM et al. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112(4), 1013-1021 (2008).
26. Limdi NA, Wadelius M, Cavallari L et al. Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18), 3827-3834 (2010).
27. Coumadin®, package insert. Bristol-Myers Squibb, Princeton, NJ, USA.
28. Gage BF, Eby C, Milligan PE et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91(1), 87-94 (2004).
29. Lenzini P, Wadelius M, Kimmel S et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin. Pharmacol. Ther. 87(5), 572-578 (2010).
30. Horne BD, Lenzini PA, Wadelius M et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb. Haemost. 107(2), 232-240 (2012).
31. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353(9154), 717-719 (1999).
32. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements - A systematic review and meta-analysis. Eur. J. Clin. Pharmacol. 65(4), 365-375 (2009).
33. Cavallari LH, Momary KM, Patel SR et al. Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol. Dis. 46(2), 147-150 (2011).
34. Perera MA, Gamazon E, Cavallari LH et al. The missing association: Sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin. Pharmacol. Ther. 89(3), 408-415 (2011).
35. Limdi NA, Beasley TM, Crowley MR et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9(10), 1445-1458 (2008).
36. Marsh S, King CR, Porche-Sorbet RM, Scott-Horton TJ, Eby CS. Population variation in VKORC1 haplotype structure. J. Thromb. Haemost. 4(2), 473-474 (2006).
37. Voora D, Koboldt DC, King CR et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87(4), 445-451 (2010).
38. Cavallari LH, Perera M, Wadelius M et al. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet. Genomics 22(2), 152-158 (2012).
39. Caldwell MD, Awad T, Johnson JA et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111(8), 4106-4112 (2008).
40. Schneider D, Lilienfeld DE, Im W. The epidemiology of pulmonary embolism: Racial contrasts in incidence and in-hospital case fatality. J. Natl Med. Assoc. 98(12), 1967-1972 (2006).
41. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics - 2011 update: A report from the American Heart Association. Circulation 123(4), E18-E209 (2011).
42. White RH, Dager WE, Zhou H, Murin S. Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb. Haemost. 96(3), 267-273 (2006).
43. Morgenstern LB, Smith MA, Lisabeth LD et al. Excess stroke in Mexican Americans compared with non-Hispanic Whites: The brain attack surveillance in corpus christi project. Am. J. Epidemiol. 160(4), 376-383 (2004).
44. Lisabeth LD, Smith MA, Sanchez BN, Brown DL. Ethnic disparities in stroke and hypertension among women: The BASIC project. Am. J. Hypertens. 21(7), 778-783 (2008).
45. Lisabeth LD, Risser JM, Brown DL et al. Stroke burden in Mexican Americans: The impact of mortality following stroke. Ann. Epidemiol. 16(1), 33-40 (2006).
46. White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb. Res. 123(Suppl. 4), S11-S17 (2009).
47. Price AL, Weale ME, Patterson N et al. Long-range LD can confound genome scans in admixed populations. Am. J. Hum. Genet. 83(1), 132-135; author reply 135-139 (2008).
48. Caldwell MD, Berg RL, Zhang KQ et al. Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 5(1), 8-16 (2007).
49. Momary KM, Shapiro NL, Viana MA et al. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 8(11), 1535-1544 (2007).
50. Millican E, Jacobsen-Lenzini PA, Milligan PE et al. Genetic-based dosing in orthopaedic patients beginning warfarin therapy. Blood 110(5), 1511-1515 (2007).
51. Schelleman H, Chen J, Chen Z et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin. Pharmacol. Ther. 84(3), 332-339 (2008).
52. Gan GG, Phipps ME, Lee MM et al. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Ann. Hematol. 90(6), 635-641 (2011).
53. Zhao F, Loke C, Rankin SC et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76(3), 210-219 (2004).
54. Yu HC, Chan TY, Critchley JA, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. Q JM 89(2), 127-135 (1996).
55. Tishkoff SA, Dietzsch E, Speed W et al. Global patterns of linkage disequilibrium at the CD4 locus and modern human origins. Science 271(5254), 1380-1387 (1996).
56. Dickmann LJ, Rettie AE, Kneller MB et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9. *5) expressed among African Americans. Mol. Pharmacol. 60(2), 382-387 (2001).
57. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet. Genomics 15(11), 779-786 (2005).
58. Blaisdell J, Jorge-Nebert LF, Coulter S et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14(8), 527-537 (2004).
59. Allabi AC, Gala JL, Horsmans Y et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin. Pharmacol. Ther. 76(2), 113-118 (2004).
60. Lui Y, Hyun-Young J, Takahashi H et al. Decreased warfarin clearance with the CYP2C9 R150H (*8) polymorphism. Clin. Pharmacol. Ther. 91(4), 660-665 (2012).
61. Mitchell C, Gregersen N, Krause A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 12(7), 953-963 (2011).
62. McDonald MG, Rieder MJ, Nakano M, Hsia CH, Rettie AE. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin cose in carriers of the V433M variant. Mol. Pharmacol. 75(6), 1337-1346 (2009).
63. Wajih N, Sane DC, Hutson SM, Wallin R. The inhibitory effect of calumenin on the vitamin K-dependent g-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. J. Biol. Chem. 279(24), 25276-25283 (2004).
64. Shahin MH, Khalifa SI, Gong Y et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet. Genomics 21(3), 130-135 (2011).
65. Rost S, Fregin A, Koch D et al. Compound heterozygous mutations in the g-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br. J. Haematol. 126(4), 546-549 (2004).
66. Kimura R, Miyashita K, Kokubo Y et al. Genotypes of vitamin K epoxide reductase, g-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res. 120(2), 181-186 (2007).
67. Chen LY, Eriksson N, Gwilliam R et al. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 106(10), 3673-3674 (2005).
68. King CR, Deych E, Milligan P et al. g-glutamyl carboxylase and its influence on warfarin dose. Thromb. Haemost. 104(4), 750-754 (2010).
69. Schwarz UI, Ritchie MD, Bradford Y et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358(10), 999-1008 (2008).
70. Wu AH, Wang P, Smith A et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: Comparison with other equations. Pharmacogenomics 9(2), 169-178 (2008).
71. Lubitz SA, Scott SA, Rothlauf EB et al. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost. 8(5), 1018-1026 (2010).
72. Huang RS, Johnatty SE, Gamazon ER et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin. Cancer. Res. 17(16), 5490-5500 (2011).
73. Gamazon ER, Zhang W, Konkashbaev A et al. SCAN: SNP and copy number annotation. Bioinformatics 26(2), 259-262 (2010).
74. Innocenti F, Cooper GM, Stanaway IB et al. Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet. 7(5), E1002078 (2011).
75. Perera MA, Limdi NA, Cavallari L et al. Novel SNPs associated with warfarin dose in a large multicenter cohort of African Americans: Genome wide association study and replication results. Circulation 124(Suppl. 1), 15518 (2011).
76. Gamazon ER, Skol AD, Perera MA. The limits of genome-wide methods for pharmacogenomics. Pharmacogenet. Genomics 22(4), 261-272 (2012).
77. Cavallari LH, Shin J, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 31(12), 1192-1207 (2011).
78. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schunemann HJ. Executive summary: Antithrombotic therapy and prevention of thrombosis (9th Edition). American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(Suppl. 2), S7-S47 (2012).
79. Flockhart DA, O'Kane D, Williams MS et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet. Med. 10(2), 139-150 (2008).
80. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study. Clin. Pharmacol. Ther. 83(3), 460-470 (2008).
81. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo warfarin effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010).
82. French B, Joo J, Geller NL et al. Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11, 108 (2010).
83. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90(4), 625-629 (2011).